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Abstract
TFE3 translocation renal cell carcinoma (tRCC) is defined by chromosomal translocations involving the TFE3 transcription
factor at chromosome Xp11.2. Genetically proven TFE3 tRCCs have a broad histologic spectrum with overlapping fea-
tures to other renal tumor subtypes. In this study, we aimed for characterizing RCCwith TFE3 protein expression. Using
next-generation whole transcriptome sequencing (RNA-Seq) as a discovery tool, we analyzed fusion transcripts, gene
expression profile, and somatic mutations in frozen tissue of one TFE3 tRCC. By applying a computational analysis
developed to call chimeric RNA molecules from paired-end RNA-Seq data, we confirmed the known TFE3 trans-
location. Its fusionpartnerSFPQhas already beendescribed as fusionpartner in tRCCs. In addition, anRNA read-through
chimera between TMED6 and COG8 as well as MET and KDR (VEGFR2) point mutations were identified. An EGFR
mutation, but no chromosomal rearrangements, was identified in a control group of five clear cell RCCs (ccRCCs).
The TFE3 tRCC could be clearly distinguished from the ccRCCs by RNA-Seq gene expression measurements using a
previously reported tRCC gene signature. In validation experiments using reverse transcription–PCR, TMED6-COG8
chimera expression was significantly higher in nine TFE3 translocated and six TFE3-expressing/non-translocated
RCCs than in 24 ccRCCs (P<.001) and22papillaryRCCs (P<.05-.07). Immunohistochemical analysis of selectedgenes
from the tRCC gene signature showed significantly higher eukaryotic translation elongation factor 1 alpha 2 (EEF1A2)
and Contactin 3 (CNTN3) expression in 16 TFE3 translocated and six TFE3-expressing/non-translocated RCCs than in
over 200 ccRCCs (P < .0001, both).
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Introduction
Xp11 (TFE3) translocation carcinomas are a separate and rare entity of
renal cell carcinoma (RCC). The frequency of such tumors is excep-
tionally high in children and young adults accounting for 20% to 75%
among childhood RCCs [1]. In contrast, the frequency of Xp11 trans-
location carcinomas in RCCs (tRCC) of adults ranges between 1%
and 5%. Still, adult Xp11 tRCCs outnumber the juvenile cases by
far because RCC is generally more often occurring in the adult popu-
lation (3%-5% vs ∼0.25%). TFE3 tRCCs are defined by chromo-
somal translocations involving the TFE3 transcription factor gene
located at chromosomal band Xp11.2. TFE3 belongs to the same
family of micropthalmia transcription factors as MITF, TFEB, and
TFEC (see Table W1 for expanded gene names). The Xp11 trans-
locations in RCC fuse TFE3 to one of several reported partner genes
including ASPSCR1 (ASPL), PRCC, NONO, SFPQ (PSF), and CLTC
[1]. TFE3 translocations also occur in alveolar soft part sarcoma [2],
perivascular epithelioid cell tumor [3], and epithelioid hemangio-
endotheliomas [4]. TFE3 tRCCs frequently share common morpho-
logic features with clear cell RCC (ccRCC) and papillary RCC
(pRCC) such as voluminous clear cytoplasm arranged in alveolar or
papillary-like structure. Additionally, they can resemble multilocular
cystic RCC or collecting duct carcinoma because they sometimes present
with cystic-like features or tubular growth pattern [1]. Psammomatous
calcification is often indicative for TFE3 rearrangements. This wide
spectrum of histologic features emphasizes the need for additional
diagnostic tools.
As severe ambiguity and restrictions apply to diagnosing TFE3
tRCC solely based on morphology and TFE3 immunohistochemistry
(IHC), a new conception of gold standard has emerged. A growing
body of data clearly demonstrates the need for additional molecular
analyses by fluorescence in situ hybridization (FISH), PCR, or other
techniques [5–8].
Over the last decade, high-throughput technologies have con-
tributed to major advances in cancer research. Next-generation
sequencing technology has the ability to inspect both cancer genomes
[9,10] and transcriptomes [11–13]. Several times, the technique has
been successfully applied to identify novel tumor-specific biomarkers
(i.e., mutations, polymorphisms, genomic rearrangements or mRNA
splice isoforms, and so on). Although the numerous TFE3 fusion
genes and the microphthalmia transcription factor family have been
extensively studied in the past, there is only limited knowledge on other
molecular alterations in TFE3 tRCC. Mutations of the von Hippel-
Lindau (VHL) tumor suppressor gene, which is inactivated in about
80% of ccRCC, or other frequently mutated genes in ccRCC coding
histone-modifying and chromatin-remodeling enzymes (e.g., PBRM1
or BAP1) [14,15] have not been found in tRCC [16]. Camparo
et al. [17] published an expression signature of 83 differentially
expressed genes in four tRCCs compared to 68 reference tumor
samples, including ccRCCs, pRCCs, chromophobe and urothelial
RCCs, oncocytomas, and normal renal tissue.
In this study, we performed next-generation whole transcriptome
sequencing (RNA-Seq) with the goal of identifying additional molecu-
lar diagnostic markers in TFE3 tRCC. We subjected the RNA-Seq
data to an algorithm (FusionSeq [18]) proven effectively in the
detection of RNA chimeras and gene fusions in prostate cancer [13],
evaluated new protein markers, and sought for point mutations in
key cancer genes.
Materials and Methods
Patients
For RNA-Seq, frozen tissue of an TFE3 tRCC stored in the
biobank of the Institute of Surgical Pathology, University Hospital
Zurich (Zurich, Switzerland) was selected. The control group included
five fresh frozen ccRCCs. The clinicopathologic data of these cases are
summarized in Table W2.
To validate RNA expression data, we studied a cohort of 16 TFE3
translocation (FISH+/IHC+) and 6 TFE3-expressing/non-translocated
(FISH−/IHC+) RCCs by IHC (Table 1). All these cases were diag-
nosed by experienced uropathologists or pediatric pathologists (H.M.,
E.C., and E.B.). The cases were collected at the University Hospital
Zurich, the Pitié-Salpêtrière Hospital (Paris, France), and the University
Hospital Basel (Basel, Switzerland). The diagnosis of these cases
was based on morphologic criteria, TFE3 IHC, and FISH. TFE3
Table 1. Characteristics of 22 TFE3 Translocation and TFE3-Expressing/Non-Translocated Cases.
Case No. TFE3 IHC TFE3 FISH Sex, Age pT N M Fuhrman Grade Cohort Comment
1 Positive Positive Female, 16 pT1b N1 Mx 2 Zurich
2 Positive Positive Female, 77 pT1b Nx Mx x Zurich Case 26 [28]
3 Positive Positive Female, 20 pT3a N1 M0 2 Zurich
4 Positive Positive Female, 22 pT1a N0 M0 2 Zurich
5 Positive Positive Female, 69 pT1b Nx Mx x Zurich
6 Positive Positive Male, 8 pT3 N1 Mx x Zurich
7 Positive Positive Female, 23 pT1b Nx Mx 2 Paris
8 Positive Positive Female, 33 pT1a N1 Mx 2 Paris
9 Positive Positive Female, 22 pT2 Nx Mx 3 Paris
10 Positive Positive Male, 29 pT2 N0 Mx 3 Paris
11 Positive Positive Female, 8 pTx Nx Mx x Basel Case 5 [19], case 8 [20]
12 Positive Positive Male, 9 pTx Nx Mx x Basel Case 7 [19], case 14 [20]
13 Positive Positive Female, 15 pTx Nx Mx x Basel Case 8 [19], case 10 [20]
14 Positive Positive Male, 13 pTx Nx Mx x Basel Case 12 [19]
15 Positive Positive Female, 11 pTx Nx Mx x Basel Case 13 [19]
16 Positive Positive Female, 19 pTx Nx Mx x Basel Case 11 [19]
17 Positive Negative Male, 41 pTx Nx M1 x Zurich
18 Positive Negative Male, 71 pT1b Nx Mx 3 Zurich
19 Positive Negative Female, 55 pT1a Nx M0 3 Zurich
20 Positive Negative Female, 54 pTx Nx Mx x Zurich
21 Positive Negative Male, 57 pT1a Nx Mx 2 Paris
22 Positive Negative Male, 87 pT3a Nx Mx 4 Paris
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expression was evaluated by IHC on whole block sections (TFE3,
sc-5958; Santa Cruz Biotechnology, Heidelberg, Germany).
Neoplasms showing moderate (2+) to strong (3+) nuclear labeling
for TFE3 visible at low power (×4-10) and weak (1+) labeling
appreciable only at high power (×20) in the absence of staining of
normal tissues were considered positive. Neoplasms with no nuclear
labeling (0+) were considered negative. Broad or focal cytoplasmic
staining was not considered.
All 22 cases were assembled to a tissue microarray (TMA) on which
each tumor was represented with two cores of 0.6-mm diameter and
further analyzed for TFE3 translocation by TFE3 break-apart FISH
(SPECTFE3Dual Color Break Apart Probe; ZytoVision, Bremerhaven,
Germany). Here, the tRCC index case served as a positive control.
Evaluation of TFE3 FISH signals was non-automated.
In addition, formalin-fixed paraffin-embedded (FFPE) tissue of
24 ccRCCs and 22 pRCCs was used for RNA extraction to perform
TaqMan assays on RNA chimeras. Two TMAs with 390 renal tumors
(274 ccRCCs, 25 type I pRCCs, 30 type II pRCCs, 18 chromophobe
RCCs, 2 collecting ducts of Bellini, 16 unclassified RCCs, 3 Wilms
tumors, and 22 oncocytomas) were used for marker protein expression
study. These TMAs have been described in [19–21]. The study was
approved by the Cantonal Ethics Committee of Zurich (KEK-ZH-Nr.
2001-0072/4).
RNA-Seq and Data Processing to Call Chimeric Transcripts
Sections (10 × 10 μm thick) were cut from frozen tumor blocks.
RNA extraction was performed using TRIzol reagent (Life Technol-
ogies, Zug, Switzerland). RNA integrity was validated by 2100 Bio-
analyzer (Agilent Technologies, Basel, Switzerland). Paired-end (PE)
RNA-Seq was conducted at Prognosys Biosciences (La Jolla, CA) using
the Genome Analyzer II from Illumina (San Diego, CA). Library
preparation was done according to existing protocols [13] with the
following parameters: 550-bp fragment length of the cDNA library
and 50- to 100-bp read length. In total, 298 Mio reads were gener-
ated, of which 151 Mio (50.8%) reads were mapped to the human
genome reference sequence (hg18) and a custom-generated splice
junction library based on UCSC Known Genes annotation data set
(Table W2). We allowed for up to two mismatches per read. We
also discarded reads that could be aligned to more than five distinct
locations in the genome. If a read could be mapped to up to five loca-
tions, the one with the best score (i.e., less number of mismatches) is
selected. As part of a standardized RNA-Seq analysis procedure in the
Gerstein Lab at Yale University [22], the data were made anonymous
and genome-wide gene and exon expression values [reads per kilobase
of the gene model per million mapped reads (RPKM)] were calculated
for all six RCCs. The PE reads were then processed through FusionSeq.
All steps in this analysis pipeline are described in detail by Sboner et al.
[18]. In brief, the program aligns all reads to the human genome (hg18)
and searches for PE reads where one read maps to gene A and the other
read maps to gene B. After filtering out artifactual PE read alignments,
it classifies remaining instances as interchromosomal, intrachromo-
somal, or cis-chromosomal rearrangements if gene A and gene B are
located on different chromosomes, same chromosome/same orienta-
tion, or same chromosome/opposed orientation, respectively. PE reads
mapping to two genes with the same orientation and located directly
adjacent on the same chromosome were designated as read-through
candidate. The software attributes confidence values to each candidate
that enables for prioritization in validation experiments. Ratio of
empirically computed supportive PE reads was used as the score to
prioritize follow-up in this study.
Gene Expression Profiling from RNA-Seq Data
We calculated gene expression from RNA-Seq data as proposed
by Mortazavi et al. [23]. All genome-wide RPKM values were quan-
tile normalized. The composite exon model used here is described in
detail elsewhere [18]. For gene expression analysis by RNA-Seq, we
selected 80 genes from the renal translocation carcinoma signature
published by Camparo et al. [17] and calculated the fold change
expression in our tRCC compared to the mean expression level of
the five ccRCCs. Three gene IDs from this signature could not be
found in our gene list. Hierarchical clustering was done with the
MultiExperiment Viewer (MeV; Dana-Farber Cancer Institute,
Boston, MA). Significance (P < .05) was calculated by one-way
analysis of variance (ANOVA) and Bonferroni correction.
Mutation Analysis Using RNA-Seq Data
DNA extraction was done with AllPrep DNA/RNA Mini Kit
(Qiagen, Hilden, Germany) from 3 × 10 μm section of the same
frozen tumor blocks used for RNA-Seq. We sought mutations in
selected oncogenes and tumor suppressor genes with specific
emphasis on critical players in RCC-specific pathways and/or genes
frequently mutated in RCC [15,24]. The following 30 genes were
selected: EGFR, KIT, BRAF, KRAS, AKT1, PIK3CA, CCND1,
CDK1, CDK2, TP53, PTEN, CDKN2A (p16), RB1, VHL, HIF1A,
EPAS1 (HIF2A), MET, MTOR, KDR (VEGFR2), FLT4 (VEGFR3),
KDM5C ( JARID1C ), KMT2D (MLL2),NBN,NF2, PMS1, SETD2,
KDM6A (UTX ),WRN, UBR4 (ZUBR1), and PBRM1. We inspected
all reads covering the exons of 30 cancer genes using the Broad
Institute’s Integrated Genome Viewer (gene model hg18) and called
base pair exchanges manually by applying the following criteria: 1)
Only high-quality reads were considered. 2) Alterations in the two
first or last positions of the reads were rejected (criterion based on
[25]; error rates increase with read length, and high error rate for
first bases in some of the reads may be due to a long first cycle process-
ing time and lack of pre-phasing or interference of the first bases with
parts of the adapter sequence). 3) A minimum of 10 covering reads
(favorably stacked) and at least 35% reads harboring the base pair
exchange (criterion set empirically to enrich high-frequency mutations).
4) Less than 10 covering reads were considered when 100% reads
harbored the exchanged base pair (criterion set empirically). Base pair
exchanges were compared to dbSNP (build 130) to filter out known
polymorphisms. Remaining somatic mutations obtained from RNA-
Seq were verified by PCR and subsequent sequencing on tumor
DNA (for primer sequences, see Table W3). The positive hits were
confirmed by a second independent PCR on tumor and normal
DNA. The functional impact of missense protein mutations was eval-
uated using MutationAssessor (http://mutationassessor.org/; Memorial
Sloan Kettering Cancer Center, New York, NY), which bases its assess-
ment on evolutionary conservation of the affected amino acid (AA) in
protein homologs. The method for detection of VHL mutations was
reported in detail [26].
Validation of Chimeric Transcripts by Reverse
Transcription–PCRs and Sanger Sequencing
cDNA was prepared using High Capacity cDNA Reverse Tran-
scription Kit (Life Technologies) from the same RNA aliquot used
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in RNA-Seq. Chimeric RNA was validated by PCR using at least
two different primer pairs per candidate. The primers were located
in exons encompassing the mRNA junction point of the two genes.
Resulting PCR bands were gel purified and sequenced on a conven-
tional ABI sequencer. Primer sequences are reported in Table W3.
TaqMan Assay for TMED6-COG8 and TFE3
Expression Measurement
RNA extraction from FFPE tissue was done as described [27] with
the following modification: instead of cutting sections, three tissue
cylinders (0.6-mm diameter) were punched from the tumor areas
of the tissue blocks. The quantitative measurements were performed
using the TaqMan RNA-to-Ct 1-step kit (Life Technologies) with
30 ng of RNA in each technical triplicate and the cycling parameters
according to the protocol on a ViiA7 (Life Technologies). Primer and
probe sequences for the TaqMan assays are given in Table W3.
Validation of Protein Markers by IHC
We selected EEF1A2, MUC1, CNTN3, SV2B, NTSR2, TRIM63,
and IGFN1 because these genes were significantly differentially
regulated and antibodies suitable for paraffin IHC were available.
For the putative TFE3 translocation and TFE3-expressing/non-
translocated RCC marker proteins SV2B (NBP1-46368; Novus
Biologicals, Cambridge, United Kingdom), NTSR2 (LS-A1265;
LifeSpan Biosciences, Seattle, WA and ab48273; Abcam, Cambridge,
United Kingdom), TRIM63/MURF1 (AP16114PU-N; Acris,
Herford, Germany), and DKFZp434B1231/IGFN1 (H91156-A01;
Abnova, Heidelberg, Germany and HPA039566; Sigma, St Gallen,
Switzerland), we were not able to establish working IHC procedures.
IHC for EEF1A2 (Human Protein Atlas, sc68481, 1:50; Santa Cruz
Biotechnology),MUC1 (NCL-MUC-1, cloneMa695, 1:50; Novocastra,
Nunningen, Switzerland), and CNTN3 (Human Protein Atlas, NBP1-
89971, 1:50; Novus Biologicals) revealed reliable results with breast
cancer, normal lung, and normal uterus as positive controls, respec-
tively. A three-graded system (0, negative; 1, weak/moderate; 2, strong)
was used to measure protein expression. Statistical testing was done
using a χ2 test with a confidence interval of 95%.
Results
Identification of Fusion Transcripts
Each tumor sample displayed variant numbers of chimeric RNA
candidates (Figure 1A). Interchromosomal, intrachromosomal, and cis-
chromosomal candidates represent the best candidates for unraveling
genomic rearrangements (see Materials and Methods section for
definition). The most promising nine candidates were selected for vali-
dation (Figure 1B). The cis candidate turned out to be a false positive
RNA chimera due to incomplete gene annotation as exemplified by
another detailed description of a false positive cis chimera in prostate
cancer [13]. GATAD1 transcription extends to include exons in the
gene region of PEX1 (data not shown).
Among the intrachromosomal and interchromosomal candidates,
solely the top candidate SFPQ-TFE3 in our tRCC index case was
verifiable. This 22-year-old patient presented with a renal tumor that
exhibited histologic features of mixed clear cell/papillary structure and
calcifications (psammoma bodies; Figure 2A). The tumor showed
strong nuclear expression of TFE3 by IHC (Figure 2B) and a TFE3
translocation by FISH (Figure 2C ). In the RNA-Seq data, 112 PE
reads connected exons of SFPQ to exons of TFE3 (Figure 2D). Reverse
transcription (RT)–PCR and sequencing confirmed the expression of
an SFPQ-TFE3 chimeric transcript (Figure 2E ). RNA-Seq is also a
useful tool for measuring exon-specific expression levels [23]. Because
of the translocation event that places TFE3 under the control of its
5′ partner’s promoter, TFE3 is overexpressed. In the tRCC, we show
for both partner genes that exons within the gene fusion transcript
have a significantly (P = .04) higher mean expression level than exons
lost in the translocation event (Figure 2E). The remaining eight gene
fusion candidates could not be validated by RT-PCR and represented
false positives.
In the tRCC, we discovered an RNA read-through candidate joining
exons of TMED6 with COG8. TMED6 was also identified in the Xp11
translocation carcinoma gene signature list, published by Camparo
et al. [17]. We verified this candidate by RT-PCR and found three dif-
ferent isoforms of theTMED6-COG8 (TC) chimera, all of them retain-
ing an N-terminally truncated COG8 open reacting frame (Figure 3A).
Compared to ccRCC, median TC levels were 1289-fold increased
in TFE3 tRCCs and 114-fold in TFE3-expressing/non-translocated
Figure 1. Overview of RNA chimera calls in six RCC samples. (A) Summary of all classes of RNA chimera calls from FusionSeq in
all samples sorted by sequencing depth. (B) Nine top-scored interchromosomal/intrachromosomal and cis candidates selected for
verification by RT-PCR.
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RCCs (Figure 3B). Compared to pRCC, the up-regulation was still 22-
fold in TFE3 tRCC and 1.9-fold in TFE3-expressing/non-
translocated RCC. Despite up-regulation of TFE3 at the protein
level, overall TFE3 RNA levels were not significantly altered among
the RCC subgroups (Figure 3C).
Gene and Protein Expression Profiles
Using RNA-Seq and data from the recently published expression
signature from Camparo et al., the tRCC displayed 48 upregulated
signature genes, of which 41 (85%) were also overexpressed in the
data set of Camparo et al. (Figure 4A). Thirty-two genes were down-
regulated, of which 27 (84%) were in concordance with Camparo
et al. Using this signature, we were able to clearly distinguish the
tRCC from the five ccRCCs.
To further validate the signature at the protein level, we investi-
gated the expression pattern of three putative marker proteins on a
TMA. Sixteen cases were translocated and had strong/moderate
nuclear TFE3 expression (termed “TFE3 tRCC”; Table 1). We
did not find TFE3 genomic rearrangements in 6 of 22 (27%) cases
displaying histologic features suggestive for TFE3 translocation but
with weak (n = 2), moderate (n = 2), or strong (n = 2) nuclear TFE3
immunoreactivity (termed “TFE3-expressing/non-translocated
RCC”). The TFE3 break-apart FISH assay was repeated on large
sections of these latter six tumors to confirm the results from the
Figure 2. Identification of SFPQ-TFE3 gene fusion in renal cancer. (A) Histology of the index TFE3 tRCC case (left panel) with a zoom in
on papillae of tumor cells with clear cytoplasm (right panel). Arrows indicate typical calcifications. (B) TFE3 IHC of tRCC (left panel)
with the nuclei of cancer cells strongly stained. No staining of the nuclei of epithelial cells lining adjacent normal (N) renal tubules
(right panel). (C) A representative cancer nucleus of tRCC displays TFE3 rearrangement. The split of a yellow signal into distinct red
and green signals marks a broken TFE3 allele. The remaining yellow signal represents the remaining intact TFE3 allele. (D) The circus
image represents a zoom in on the genomic location of the SFPQ gene (orange) on chromosome 1 (brown) and the TFE3 gene (purple)
on chromosome X (gray). Exons are displayed in green. PE reads (red) connect SFPQ (NM_005066.2) 5′ exons to TFE3 (NM_006521.4)
3′ exons. (E) The fusion transcript consists of SFPQ exons 1 to 7 and TFE3 exons 6 to 10 (lower panel). Red dots represent the expres-
sion value per exon of the tRCC; gray dots represent the mean expression value per exon of the other five ccRCC samples combined.
The lines mark the mean expression value of exons within the fusion transcript and exons lost in the fusion event. For both genes, these
two groups of exons display a significant difference in expression in the translocation case (red lines) but not in the other RCCs (gray
dotted lines).
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small TMA cores and to rule out tumor heterogeneity. Here, TFE3was
not rearranged either.
EEF1A2 and CNTN3 were chosen as marker genes overexpressed
in TFE3 tRCCs andMUC1 as a downregulated gene. Loss of MUC1
expression is observed in TFE3 tRCC (56%) but also in the common
subtypes such as ccRCC (18%) and pRCC (21%), as well as in un-
classified RCC (44%), chromophobe (6%), and oncocytomas (5%;
Figure 4B). Strong EEF1A2 expression was seen in both TFE3 trans-
location (88%) and TFE3-expressing/non-translocated RCCs (50%).
Only a minor fraction of pRCC (15%) and ccRCC (1%), as well as
unclassified RCC (10%) also had such strong expression of EEF1A2.
CNTN3 expression was more diverse; although 19% TFE3 tRCCs
and 67% TFE3-expressing/non-translocated RCCs displayed strong
CNTN3 expression compared to only 4% of ccRCC, levels were
also high in the papillary subtype, oncocytomas, Wilms tumors,
and unclassified RCC (14%-33%).
Mutation Analysis
To identify mutations using RNA-Seq data, we manually called
base pair exchanges in the genes’ coding sequences (CDSs) and un-
translated regions. In total, we identified 288 base pair exchanges that
met the criteria (see Materials andMethods section). Most of them (n =
263) were located in the CDS (Table 2). In the CDS, 220 (84%)
were discarded as known single-nucleotide polymorphisms (SNPs)
and 43 (16%) were further analyzed by RT-PCR and Sanger
sequencing (green-labeled in Table W4). In the tRCC, we identified
two heterozygous germline mutations in exon 2 of the MET gene
and in exon 16 of the KDR VEGFR2 gene. The G24E AA exchange
in MET pertains to the N-terminal signal peptide region, whereas the
A757G exchange of VEGFR2 is located in the extracellular domain.
In ccRCC-5, we found a heterozygous, somatic [C/T] mutation in
exon 23 of EGFR (Figure 5). The mutation is located in the tyrosine
kinase domain of the EGFR, and MutationAssessor predicted a high
functional impact of the R932C AA exchange.
Discussion
Using RNA-Seq, we discovered that high levels of the TMED6-COG8
RNA read-through chimera and elevated expression of EEF1A2 and
CNTN3 protein are potential molecular markers of TFE3 transloca-
tion and TFE3-expressing/non-translocated RCCs. In addition,
RNA-Seq allowed identification of SFPQ as fusion partner in a
TFE3 tRCC, as well as mutations in the therapeutically relevant genes
MET and VEGFR2.
Our index case for TFE3 translocation (tRCC) showed an SFPQ-
TFE3 gene fusion, which may not be as frequent as ASPL-TFE3 or
PRCC-TFE3 fusions. For RCC, a minimum of 13 PRCC-TFE3 and
ASPL-TFE3 fusions each is reported, as genetically confirmed in
several studies [17,28–30]. A minimum of five RCC cases of geneti-
cally confirmed SFPQ-TFE3 fusions exists in the literature [17,28,30].
Interestingly, five SFPQ-TFE3 tRCCs were intermingled in a cohort
of more than 400 histologically diagnosed ccRCC cases [16], demon-
strating the difficult differential diagnosis between ccRCC and TFE3
tRCC, because both tumor types share some morphologic features.
SFPQ-TFE3 fusions are also found in perivascular epithelioid cell
tumors; the case reported by Tanaka et al. [31] located to the gastro-
intestinal tract and expressed a fusion transcript between SFPQ exon 7
and TFE3 exon 5.
In our attempt to identify novel gene fusions in RCC, we were con-
fronted with some low-score gene fusion candidates. Although we
reconciled with the Mitelman Database of Chromosome Aberrations
Figure 3. TMED6-COG8 (TC) read-through in RCC. (A) DNA: Schematic representation of the genomic structure of TMED6 and COG8 on
the DNA (−) strand. RNA: Three isoforms were expressed with TCv1 being the prominent one. The TaqMan assay used to detect TC
levels in RCCs is indicated. Protein: Two isoforms encode N-terminally truncated COG8 from an alternative ATG START sites down-
stream of the original one in COG8 exon 1. The TCv3 isoform uses an ATG provided by the TMED6 sequence. The COG8 CDS is given
in green, and the small appendage on the N-terminus in TCv3 is given in brown. (B) TMED6-COG8 (TCv1) levels were measured in FFPE
samples of TFE3 translocation (median expression at 467,735) and TFE3-expressing/non-translocated RCCs (at 41,210) and compared to
ccRCCs (at 363) and pRCCs (at 21,627); ***P < .001 and *P < .05; ns, not significant. (C) Total TFE3 expression encompassing the
fusion transcripts measuring levels of exons 8 and 9.
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and Gene Fusions in Cancer (http://cgap.nci.nih.gov/Chromosomes/
Mitelman), we found none of these partner genes involved in genomic
rearrangements in renal or other cancer types. This and their low prob-
ability score indicate them as artificial candidates likely generated
during library preparation. This is also consistent with the recent data
from the Cancer Genome Atlas Research Network, which did not
report any new chromosomal rearrangements in 400 ccRCCs [16].
Importantly, we identified TMED6-COG8 (TC) as a novel RNA
read-through molecule with elevated expression in TFE3 translocation
and TFE3-expressing/non-translocated RCCs. RNA read-throughs
Figure 4. Gene expression profile from RNA-Seq data supports a known renal translocation signature. (A) The heat map is a represen-
tation of expression values of 80 signature genes. The genes are sorted according to their fold change expression difference between
the tRCC and the mean value of the other five ccRCCs. Significant genes (corrected P < .05) are marked by asterisk. On the left, the
genes were ranked according to fold change expression difference by Camparo et al. [17]. (B) Expression pattern of marker genes
selected from A across different RCC subtypes. Significance was calculated by χ 2 test.
Table 2. Base Pair Exchange Calls in RNA-Seq Data.
tRCC ccRCC-1 ccRCC-2 ccRCC-3 ccRCC-4 ccRCC-5 Total
n % n % n % n % n % n % N %
Total 68 61 23 37 50 49 288
Untranslated region 2 3 9 15 1 4 2 5 8 16 3 6 25 9
CDS 66 97 52 85 22 96 35 95 42 84 46 94 263 91
SNP 60 91 38 73 20 91 29 83 29 69 44 96 220 84
No SNP 6 9 14 27 2 9 6 17 13 31 2 4 43 16
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are evolving as a novel class of tumor markers, an example being
SLC45A3-ELK4 in prostate cancer [32,33]. It was regarded as an
important finding because it is the first description of an RNA read-
through detectable in urine of patients with prostate cancer due to
its hormone-dependent overexpression. The elevated expression of
TC may point to a potential diagnostic marker for TFE3 tRCCs, be-
cause TCv1 expression was significantly higher in TFE3 tRCCs com-
pared to ccRCC and pRCC in our TaqMan assay. TMED6 is highly
expressed in α cells of the pancreatic islets and is associated with in-
sulin production and secretion [34]. COG8 is part of a multiprotein
complex in the Golgi apparatus and responsible for intracellular traffick-
ing and protein glycosylation [35]. It is possible that the read-through
event with TMED6 leads to an up-regulation of an N-terminally trun-
cated COG8 protein. We can only hypothesize about its function in
RCC. TC read-through may prove detectable at the RNA level not
only in tissue but also in urine, blood, or circulating tumor cells of
patients with TFE3 tRCC. Moreover, up-regulation of TC levels also
in TFE3-expessing/non-translocated RCCs suggests a common biologic
mechanism shared with TFE3 tRCCs.
Using RNA-Seq and data from the recently published expression
signature [17], we were able to separate our tRCC from ccRCCs,
implying that the list of differentially expressed genes by Camparo
Figure 5. Rare mutations in renal cancer affecting EGFR, MET, and KDR. Three mutations occurring in two RCC samples are given with
exact genomic location, base pair, and AA exchange and the percentage of reads that have the mutated allele in the RNA-Seq data.
Only the unique reads covering the mutated base are displayed below. Each mutation was evaluated by PCR and conventional Sanger
sequencing in tumor and corresponding normal tissue.
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et al. appears as a robust signature for TFE3 tRCC. To further vali-
date specific proteins of this signature, we studied EEF1A2,
CNTN3, and MUC1 IHC in several renal cancer subtypes. EEF1A2
is a subunit of the eukaryotic translation elongation factor 1 protein
complex delivering tRNA to the ribosome. The alpha 2 isoform is usu-
ally expressed in the brain, heart, and skeletal muscle, but high levels are
also characteristic for carcinogenesis including breast [36], ovarian [37],
and prostate [38] cancers. CNTN3 is the third member of the Con-
tactin family of cell surface proteins. Like Contactins 1 and 2, it is
expressed at high levels in the nervous system, but high expression
was also found in plasmocytomas [39]. TFE3 tRCCs underexpress
epithelial IHC markers such as MUC1, also known as epithelial mem-
brane antigen (EMA) [40]. Loss of MUC1 is used in addition to TFE3
IHC to support the diagnosis of a translocation carcinoma. However,
our data show a significant portion of ccRCC also being negative for
MUC1 expression impairing differential diagnosis. IHC for TFE3
protein has proven to be a highly sensitive and specific assay for the
TFE3 tRCC [41], but this assay detects also native TFE3, which is
ubiquitously expressed at very low levels. This can lead to false-positive
results. In addition, TFE3 IHC is highly dependent on the tissues’
formalin fixation. Therefore, the TFE3 FISH assay is recommended
to detect TFE3 gene rearrangements in cases with equivocal TFE3
IHC results [42]. However, both assays are difficult to interpret when
only archival FFPE tissue blocks are available. In the course of our
study, we analyzed our cohort of TFE3 immunopositive cases by FISH.
Six of 22 (27%) tumors displaying typical histologic features of TFE3
tRCC had no TFE3 rearrangements by FISH, which was also con-
firmed by reanalyzing large sections. Other examples of such RCCs
have been reported previously at comparable frequencies [6 of 21
(28%) [7] and 5 of 11 (45%) [30]]. Green et al. [42] suggest the exis-
tence of unclassified RCC, which are biologically related to TFE3
tRCC with TFE3 and cathepsin K expression in the absence of
TFE3 rearrangements. They suspect that other mechanisms than
chromosome translocation can affect TFE3 expression. Such a biologic
relationship between TFE3 translocation and TFE3-expressing/
non-translocated tumors is supported by our biomarker analysis.
Compared to ccRCC, pronounced overexpression of TMED6-
COG8 and EEF1A2 was characteristic for both TFE3 tRCCs and
TFE3-expressing/non-translocated RCCs. Of note though are the
differences between TFE3 translocation and TFE3-expressing/
non-translocated tumors regarding CNTN3 and MUC1 expression.
We conclude that MUC1 and CNTN3 have limited practical value
in routine diagnostics due to the mixed expression pattern in between
the spectrum of all tumor subtypes.
The mutations detected in our study occurred in three clinically
relevant genes that are rarely affected in RCC and therefore not part
of routine diagnostic protocols. All three mutations are unknown in
the Catalogue of Somatic Mutations in Cancer and are not listed
among the few entries of EGFR, MET, and KDR mutations in
RCC samples.
The identified MET and VEGFR2 mutations were both germline
and occurred in a TFE3 tRCC. Germline MET mutations are associ-
ated with a hereditary form of pRCC hereditary papillary renal carci-
noma type 1 (HPRC 1) [43]. Although both mutations separately
might not be causal, they might exert synergistic effects on tumor
development in this young patient with TFE3 tRCC. Recently, it
has been shown in a phase II trial that germline MET mutations in
patients with pRCC are highly predictive of response to Foretinib, a
drug targeting both MET and VEGFR2 [44]. It remains to be
elucidated if TFE3 tRCCs may be prone to acquire MET mutations,
and more functional evidence is needed before we can conclude the
usefulness of this inhibitor in treating this RCC subtype.
Interestingly, we detected an EGFR mutation in one case of
ccRCC. Most activating and cancer-driving mutations in EGFR are
located between exons 18 and 21. The tyrosine kinase domain covers
268 AAs spanning exons 18 to 24; p.R932C is in exon 23; hence,
this mutation could be critical. EGFR mutations are extremely rare
in RCC, and none was found in a series of 63 RCCs [45]. How-
ever, this study focused on the hotspot exons 18 to 21 only. To
exclude the possibility of hotspot mutations outside exons 18 to 21,
we sequenced exons 18 to 23 in 10 VHL wild-type ccRCCs from
our institute but failed to find more cases with EGFR mutations (data
not shown).
Mutation detection from next-generation sequencing data is strongly
dependent on the mutation type and data quantity and quality. Small
insertions/deletions or high GC content might impair the alignment
of reads to target genes. Both factors are contributing to the inability
to confirm the known VHL mutations in our three ccRCC samples
(data not shown).
In summary, the application of the FusionSeq algorithm [18] to our
RNA-Seq data has proven highly successful in the detection of RNA
chimeras and gene fusions in TFE3 translocation cancer. We ob-
tained new markers for TFE3 translocation and TFE3-expressing/
non-translocated RCCs and identified relevant point mutations.
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